Insights On Outsourced Drug Development

  1. Scale-Up Of A Transient rAAV Production Process 11/3/2025

    Scalable rAAV production is achievable with a transient cell line and optimized bioreactor setup, delivering high titers and reduced impurities, now validated at 200 L scale for commercial readiness.

  2. How Solid-State Science Solves Your Toughest API Challenges 6/3/2026

    Difficult small molecules demand more than standard purification strategies. See how combining solid-state expertise with advanced chromatographic modeling improves filtration, purity, and scalability.

  3. Formulation Of Crystalline Nanoparticles Enabling Superior Drug Load 8/13/2024

    Explore how bioavailability of poorly soluble APIs can be improved and patient compliance enhanced by reducing the size or number of tablets that a patient must take to achieve the required dose.

  4. The Patent Cliff Looms – Design Your Biosimilar Approach Accordingly 3/3/2025

    In your pursuit of developing a high-quality biosimilar, think strategically. Consider what type of biologic your team’s expertise can support and which is needed most in your target market.

  5. Chirality In Drug Development: From Racemic Mixtures To Enantiopure Substances 5/6/2026

    Chiral crystallization enables efficient production of enantiopure drug substances, improving pharmacological control and safety while supporting scalable, cost‑effective small molecule development.

  6. Transformative Innovation: Advancing Drug Development Using In Silico Modeling 3/4/2026

    Explore how predictive modeling and in silico strategies can turn complex data into actionable insights that accelerate drug development and reduce risk across the development lifecycle.

  7. Integrating Phase-Appropriate Quality Standards 12/9/2024

    Incorporating phase-specific quality standards ensures GMP compliance. Collaborating with an experienced CDMO addresses late-stage quality needs and efficiently manages development timelines.

  8. A Simple And Powerful Solution For Accelerating Dissolution 5/5/2026

    Many poorly soluble drugs fail not because of low solubility, but because they dissolve too slowly. Learn how focusing on dissolution rate can unlock absorption gains using simple strategies.

  9. Expanding Translational Research Concepts With Genedata Profiler 11/26/2024

    The biopharma industry leverages Genedata Profiler to integrate, curate, and analyze diverse R&D data, enabling collaborative, compliant, and AI-driven translational research to optimize drug development.

  10. Enabling Quality By Design 9/8/2025

    Outdated quality systems delay product release. Discover how manufacturers can harness real-time data, operationalize QbD, and enhance compliance, efficiency, and supply chain continuity.